US 12,492,264 B2
Anti-ROR1 antibody and ROR1-targeting engineered cells
Vita Golubovskaya, Pinole, CA (US); and Lijun Wu, Albany, CA (US)
Assigned to Caribou Biosciences, Inc., Berkeley, CA (US)
Filed by Caribou Biosciences, Inc., Berkeley, CA (US)
Filed on Feb. 1, 2024, as Appl. No. 18/430,202.
Application 18/430,202 is a continuation of application No. 18/321,655, filed on May 22, 2023, granted, now 11,932,703.
Claims priority of provisional application 63/365,230, filed on May 24, 2022.
Prior Publication US 2024/0239918 A1, Jul. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/40 (2006.01); C07K 14/725 (2006.01)
CPC C07K 16/40 (2013.01) [C07K 14/7051 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01)] 9 Claims
 
1. A method of treating a ROR1-positive tumor comprising administering to a patient having a tumor a therapeutic composition comprising an immune cell comprising an anti-ROR1 chimeric antigen receptor (CAR), wherein the CAR comprises a single-chain variable fragment (scFv) having a heavy chain variable region (VH) and a light chain variable region (VL), and the VH comprises SEQ ID NO: 17, and the VL comprises SEQ ID NO: 18.